Alnylam Pharmaceuticals (ALNY) PT Raised to $125 at Needham & Company
Needham & Company analyst Alan Carr raised his price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $125.00 (from $85.00) while maintaining a Buy rating after the company announced positive top-line results from Phase 3 APOLLO trial in TTR Amyloidosis.
"Notably, primary mNIS+7 and key secondary Norfolk QOL-DN endpoint values improved from baseline, suggesting patisiran capable of more than simply slowing disease progression," Carr commented.